Vincristine sulfate (Synonyms: 硫酸长春新碱; Leurocristine sulfate; NSC-67574 sulfate; 22-Oxovincaleukoblastine sulfate)

目录号: HY-N0488 纯度: 99.81%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

Vincristine sulfate是一种抗肿瘤长春花生物碱，抑制有丝分裂纺锤体中的 microtubule 形成，导致中期阶段的分裂细胞停滞。它与 microtubule 结合的 K_i 为85 nM。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Vincristine sulfate Chemical Structure

CAS No. : 2068-78-2

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥616	In-stock
5 mg	￥350	In-stock
10 mg	￥560	In-stock
50 mg	￥2102	In-stock
100 mg	￥3412	In-stock
200 mg	现货	询价
500 mg		询价
1 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Vincristine sulfate:

MCE 顾客使用本产品发表的 51 篇科研文献

: Vincristine sulfate purchased from MCE. Usage Cited in: Int J Biol Macromol. 2019 Jan 30;128:574-582. [Abstract]; SGC7901/DDP or SGC7901/VCR cells are transfectedwith si-Con or si-ERK, and transfection efficiency is evaluated by western blot assay at 48 h post transfection.

Vincristine sulfate 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Vincristine sulfate is an antitumor vinca alkaloid which inhibits microtubule formation in mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. It binds to microtubule with a K_i of 85 nM.

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	171.5 nM Compound: Vincristine sulphate	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28038323]
A549	IC₅₀	20 nM Compound: Vincristine sulfate	Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay	[PMID: 23215348]
BT-549	IC₅₀	54.72 nM Compound: Vincristine sulphate	Antiproliferative activity against human BT549 cells after 48 hrs by MTT assay Antiproliferative activity against human BT549 cells after 48 hrs by MTT assay	[PMID: 28038323]
Cancer cell lines	GI₅₀	0.1 μM Compound: Vincristine sulfate	Cytotoxicity against human colon cancer cells after 48 hrs Cytotoxicity against human colon cancer cells after 48 hrs	[PMID: 24747749]
Cancer cell lines	GI₅₀	0.1 μM Compound: vincristine sulfate	Growth inhibition of human colon cancer cells after 48 hrs Growth inhibition of human colon cancer cells after 48 hrs	[PMID: 20684599]
Cancer cell lines	GI₅₀	0.1 μM Compound: Vincristine sulfate	Growth inhibition of human colon cancer cell by NCI-CLS assay Growth inhibition of human colon cancer cell by NCI-CLS assay	[PMID: 20395150]
Cancer cell lines	GI₅₀	0.1 μM Compound: Vincristine sulfate	Growth inhibition of human CNS cancer cell by NCI-CLS assay Growth inhibition of human CNS cancer cell by NCI-CLS assay	[PMID: 20395150]
Cancer cell lines	GI₅₀	0.1 μM Compound: Vincristine sulfate	Growth inhibition of human prostate cancer cell by NCI-CLS assay Growth inhibition of human prostate cancer cell by NCI-CLS assay	[PMID: 20395150]
Cancer cell lines	GI₅₀	0.13 μM Compound: Vincristine sulfate	Cytotoxicity against human prostate cancer cells after 48 hrs Cytotoxicity against human prostate cancer cells after 48 hrs	[PMID: 24747749]
Cancer cell lines	GI₅₀	0.13 μM Compound: Vincristine sulfate	Cytotoxicity against human CNS cancer cells after 48 hrs Cytotoxicity against human CNS cancer cells after 48 hrs	[PMID: 24747749]
Cancer cell lines	GI₅₀	0.13 μM Compound: vincristine sulfate	Cytotoxicity against human CNS cancer cells after 48 hrs Cytotoxicity against human CNS cancer cells after 48 hrs	[PMID: 22283430]
Cancer cell lines	GI₅₀	0.13 μM Compound: vincristine sulfate	Cytotoxicity against human prostate cancer cells after 48 hrs Cytotoxicity against human prostate cancer cells after 48 hrs	[PMID: 22283430]
Cancer cell lines	GI₅₀	0.13 μM Compound: vincristine sulfate	Growth inhibition of human CNS cancer cells after 48 hrs Growth inhibition of human CNS cancer cells after 48 hrs	[PMID: 20684599]
Cancer cell lines	GI₅₀	0.13 μM Compound: vincristine sulfate	Growth inhibition of human prostate cancer cells after 48 hrs Growth inhibition of human prostate cancer cells after 48 hrs	[PMID: 20684599]
Cancer cell lines	GI₅₀	0.3 μM Compound: Vincristine sulfate	Growth inhibition of human ovarian cancer cell by NCI-CLS assay Growth inhibition of human ovarian cancer cell by NCI-CLS assay	[PMID: 20395150]
Cancer cell lines	GI₅₀	0.3 μM Compound: Vincristine sulfate	Growth inhibition of human renal cancer cell by NCI-CLS assay Growth inhibition of human renal cancer cell by NCI-CLS assay	[PMID: 20395150]
Cancer cell lines	GI₅₀	0.3 μM Compound: Vincristine sulfate	Growth inhibition of human breast cancer cell by NCI-CLS assay Growth inhibition of human breast cancer cell by NCI-CLS assay	[PMID: 20395150]
Cancer cell lines	GI₅₀	0.32 μM Compound: Vincristine sulfate	Cytotoxicity against human ovarian cancer cells after 48 hrs Cytotoxicity against human ovarian cancer cells after 48 hrs	[PMID: 24747749]
Cancer cell lines	GI₅₀	0.32 μM Compound: Vincristine sulfate	Cytotoxicity against human renal cancer cells after 48 hrs Cytotoxicity against human renal cancer cells after 48 hrs	[PMID: 24747749]
Cancer cell lines	GI₅₀	0.32 μM Compound: Vincristine sulfate	Cytotoxicity against human breast cancer cells after 48 hrs Cytotoxicity against human breast cancer cells after 48 hrs	[PMID: 24747749]
Cancer cell lines	GI₅₀	0.32 μM Compound: vincristine sulfate	Cytotoxicity against human ovarian cancer cells after 48 hrs Cytotoxicity against human ovarian cancer cells after 48 hrs	[PMID: 22283430]
Cancer cell lines	GI₅₀	0.32 μM Compound: vincristine sulfate	Cytotoxicity against human renal cancer cells after 48 hrs Cytotoxicity against human renal cancer cells after 48 hrs	[PMID: 22283430]
Cancer cell lines	GI₅₀	0.32 μM Compound: vincristine sulfate	Cytotoxicity against human breast cancer cells after 48 hrs Cytotoxicity against human breast cancer cells after 48 hrs	[PMID: 22283430]
Cancer cell lines	GI₅₀	0.32 μM Compound: vincristine sulfate	Growth inhibition of human Ovarian cancer cells after 48 hrs Growth inhibition of human Ovarian cancer cells after 48 hrs	[PMID: 20684599]
Cancer cell lines	GI₅₀	0.32 μM Compound: vincristine sulfate	Growth inhibition of human renal cancer cells after 48 hrs Growth inhibition of human renal cancer cells after 48 hrs	[PMID: 20684599]
Cancer cell lines	GI₅₀	0.32 μM Compound: vincristine sulfate	Growth inhibition of human breast cancer cells after 48 hrs Growth inhibition of human breast cancer cells after 48 hrs	[PMID: 20684599]
DU-145	IC₅₀	71.83 μM Compound: Vincristine sulphate	Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 29174816]
DU-145	IC₅₀	72.3 nM Compound: Vincristine sulphate	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 28038323]
HEK293	IC₅₀	31 nM Compound: Vincristine sulfate	Cytotoxicity against human HEK cells after 72 hrs by alamar blue assay Cytotoxicity against human HEK cells after 72 hrs by alamar blue assay	[PMID: 23215348]
HeLa	IC₅₀	0.0358 μM Compound: Vincristine sulfate	Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay	[PMID: 23489291]
HeLa	IC₅₀	36 nM Compound: Vincristine sulfate	Cytotoxicity against human HeLa cells after 72 hrs by alamar blue assay Cytotoxicity against human HeLa cells after 72 hrs by alamar blue assay	[PMID: 23215348]
HepG2	IC₅₀	0.69 μM Compound: 2; VCR.H2SO4	Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay	[PMID: 26522953]
HL-60	IC₅₀	11.2 μg/mL Compound: vincristine sulfate	Cytotoxicity against human HL60 cells after 48 hrs Cytotoxicity against human HL60 cells after 48 hrs	[PMID: 17432904]
KB	IC₅₀	0.02 μM Compound: 2; VCR.H2SO4	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 26522953]
L02	IC₅₀	28.4 μg/mL Compound: vincristine sulfate	Cytotoxicity against human L02 cells after 48 hrs Cytotoxicity against human L02 cells after 48 hrs	[PMID: 17432904]
Leukemia cell	GI₅₀	0.1 μM Compound: Vincristine sulfate	Cytotoxicity against human leukemia cells after 48 hrs Cytotoxicity against human leukemia cells after 48 hrs	[PMID: 24747749]
Leukemia cell	GI₅₀	0.1 μM Compound: vincristine sulfate	Cytotoxicity against human leukemia cells after 48 hrs Cytotoxicity against human leukemia cells after 48 hrs	[PMID: 22283430]
Leukemia cell	GI₅₀	0.1 μM Compound: vincristine sulfate	Growth inhibition of human leukemia cells after 48 hrs Growth inhibition of human leukemia cells after 48 hrs	[PMID: 20684599]
Leukemia cell	GI₅₀	0.1 μM Compound: Vincristine sulfate	Growth inhibition of human leukemia cell by NCI-CLS assay Growth inhibition of human leukemia cell by NCI-CLS assay	[PMID: 20395150]
LNCaP	IC₅₀	0.0029 μM Compound: Vincristine sulphate	Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay	[PMID: 20732809]
LNCaP	IC₅₀	6.1 nM Compound: Vincristine sulfate	Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay	[PMID: 23215348]
Lu1	IC₅₀	0.48 μM Compound: 2; VCR.H2SO4	Cytotoxicity against human Lu1 cells after 72 hrs by SRB assay Cytotoxicity against human Lu1 cells after 72 hrs by SRB assay	[PMID: 26522953]
MCF7	IC₅₀	0.51 μM Compound: 2; VCR.H2SO4	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 26522953]
MDA-MB-231	IC₅₀	116.6 nM Compound: Vincristine sulphate	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 28038323]
Melanoma cell	GI₅₀	0.16 μM Compound: Vincristine sulfate	Cytotoxicity against human melanoma cells after 48 hrs Cytotoxicity against human melanoma cells after 48 hrs	[PMID: 24747749]
Melanoma cell	GI₅₀	0.16 μM Compound: vincristine sulfate	Cytotoxicity against human melanoma cells after 48 hrs Cytotoxicity against human melanoma cells after 48 hrs	[PMID: 22283430]
Melanoma cell	GI₅₀	0.16 μM Compound: vincristine sulfate	Growth inhibition of human melanoma cells after 48 hrs Growth inhibition of human melanoma cells after 48 hrs	[PMID: 20684599]
Melanoma cell	GI₅₀	0.2 μM Compound: Vincristine sulfate	Growth inhibition of human melanoma cell by NCI-CLS assay Growth inhibition of human melanoma cell by NCI-CLS assay	[PMID: 20395150]
NFF	IC₅₀	0.0169 μM Compound: Vincristine sulfate	Cytotoxicity against human NFF cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay Cytotoxicity against human NFF cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay	[PMID: 23489291]
NFF	IC₅₀	17 nM Compound: Vincristine sulfate	Cytotoxicity against human NFF cells after 72 hrs by alamar blue assay Cytotoxicity against human NFF cells after 72 hrs by alamar blue assay	[PMID: 23215348]
NSCLC	GI₅₀	0.2 μM Compound: Vincristine sulfate	Growth inhibition of human NSCLC cell by NCI-CLS assay Growth inhibition of human NSCLC cell by NCI-CLS assay	[PMID: 20395150]
NSCLC	GI₅₀	0.25 μM Compound: Vincristine sulfate	Cytotoxicity against human NSCLC cells after 48 hrs Cytotoxicity against human NSCLC cells after 48 hrs	[PMID: 24747749]
NSCLC	GI₅₀	0.25 μM Compound: vincristine sulfate	Cytotoxicity against human NSCLC cells after 48 hrs Cytotoxicity against human NSCLC cells after 48 hrs	[PMID: 22283430]
NSCLC	GI₅₀	0.25 μM Compound: vincristine sulfate	Growth inhibition of human NSCLC cells after 48 hrs Growth inhibition of human NSCLC cells after 48 hrs	[PMID: 20684599]
PC-3	IC₅₀	0.011 μM Compound: Vincristine sulphate	Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay	[PMID: 20732809]
PC-3	IC₅₀	0.0153 μM Compound: Vincristine sulfate	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay	[PMID: 23489291]
PC-3	IC₅₀	15 nM Compound: Vincristine sulfate	Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay	[PMID: 23215348]
PC-3	IC₅₀	27.6 nM Compound: Vincristine sulphate	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28038323]
PC-3	IC₅₀	28.11 μM Compound: Vincristine sulphate	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 29174816]
SMMC-7721	IC₅₀	26.7 μg/mL Compound: vincristine sulfate	Cytotoxicity against human SMMC7721 cells after 48 hrs Cytotoxicity against human SMMC7721 cells after 48 hrs	[PMID: 17432904]

体外研究
(In Vitro)

Vincristine sulfate 抑制稳态微管组装末端微管蛋白二聚体的净增加，K_i 为 85 nM^[1]。Vincristine sulfate 稳定纺锤体，导致染色体无法分离，从而导致中期停滞和低浓度有丝分裂抑制。在较高浓度下，Vincristine sulfate 可能会破坏并诱导微管完全解聚^[2]。Vincristine sulfate 诱导肿瘤细胞凋亡并抑制 SH-SY5Y 细胞增殖，IC₅₀ 为 0.1 μM。Vincristine sulfate 诱导有丝分裂停滞并促进 caspase-3 和 -9 及细胞周期蛋白 B 的表达，同时降低细胞周期蛋白 D 的表达^[3]。Vincristine sulfate 引起的神经毒性是由微管功能干扰引起的，这会导致轴突运输受阻，从而导致轴突变性^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Vincristine（3 mg/kg，腹腔注射）诱导平均生长延迟 > 120 和 > 52 天，并重新填充 0.06% 和 5% 的分数，分别在携带双侧皮下异种移植 Rh12 或 Rh18 的小鼠中施用^[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

923.04

Formula

C₄₆H₅₈N₄O₁₄S

CAS 号

2068-78-2

性状

固体

颜色

White to off-white

中文名称

硫酸长春新碱；硫酸长春醛碱；长春新碱硫化物；长春新碱硫酸盐

结构分类

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

溶解性数据

细胞实验：

DMSO 中的溶解度 : 83.33 mg/mL (90.28 mM; 超声助溶 (<80°C); 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : 50 mg/mL (54.17 mM; 超声助溶)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.0834 mL	5.4169 mL	10.8338 mL
5 mM	0.2167 mL	1.0834 mL	2.1668 mL
10 mM	0.1083 mL	0.5417 mL	1.0834 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (2.25 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (2.25 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (2.25 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： PBS
Solubility: 100 mg/mL (108.34 mM); 澄清溶液; 超声助溶 (<60°C)

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

计算结果

工作液所需浓度 : mg/mL

该产品水溶性佳，请具体参考实测水 / PBS / Saline 中的溶解度数据。

您所需的储备液浓度超过该产品的实测溶解度，如有需要，请与 MCE 中国技术支持联系。

纯度 & 产品资料

纯度: 99.81%

选择批次：

Data Sheet (658 KB) SDS (644 KB)

COA (304 KB) HNMR (312 KB) LCMS (98 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Jordan, M.A., et al. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res, 1985. 45(6): p. 2741-7. [Content Brief]

[2]. Gidding, C.E., et al, Vincristine revisited. Crit Rev Oncol Hematol, 1999. 29(3): p. 267-87. [Content Brief]

[3]. Donoso, J.A., et al, Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on axonal fibrillar organelles in vitro. Cancer Res, 1977. 37(5): p. 1401-7. [Content Brief]

[4]. Horton, J.K., et al. Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochem Pharmacol, 1988. 37(20): p. 3995-4000. [Content Brief]

[5]. Baguley, B.C., et al, Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer, 1991. 27(4): p. 482-7. [Content Brief]

[6]. Zhang D, et al. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance. Int J Nanomedicine. 2017 Mar 16;12:2081-2108. [Content Brief]

Cell Assay ^[1]	Cells are plated in 2 mL of medium in 35 mm plates at a concentration of about 5×10⁴ cells/mL and grow for 24 h at 37°C in an atmosphere of 5% CO₂ and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Jordan, M.A., et al. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res, 1985. 45(6): p. 2741-7. [Content Brief] [2]. Gidding, C.E., et al, Vincristine revisited. Crit Rev Oncol Hematol, 1999. 29(3): p. 267-87. [Content Brief] [3]. Donoso, J.A., et al, Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on axonal fibrillar organelles in vitro. Cancer Res, 1977. 37(5): p. 1401-7. [Content Brief] [4]. Horton, J.K., et al. Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochem Pharmacol, 1988. 37(20): p. 3995-4000. [Content Brief] [5]. Baguley, B.C., et al, Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer, 1991. 27(4): p. 482-7. [Content Brief] [6]. Zhang D, et al. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance. Int J Nanomedicine. 2017 Mar 16;12:2081-2108. [Content Brief]

Cell Assay
^[1]

Cells are plated in 2 mL of medium in 35 mm plates at a concentration of about 5×10⁴ cells/mL and grow for 24 h at 37°C in an atmosphere of 5% CO₂ and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[1]. Jordan, M.A., et al. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res, 1985. 45(6): p. 2741-7. [Content Brief]

[2]. Gidding, C.E., et al, Vincristine revisited. Crit Rev Oncol Hematol, 1999. 29(3): p. 267-87. [Content Brief]

[3]. Donoso, J.A., et al, Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on axonal fibrillar organelles in vitro. Cancer Res, 1977. 37(5): p. 1401-7. [Content Brief]

[4]. Horton, J.K., et al. Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochem Pharmacol, 1988. 37(20): p. 3995-4000. [Content Brief]

[5]. Baguley, B.C., et al, Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer, 1991. 27(4): p. 482-7. [Content Brief]

[6]. Zhang D, et al. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance. Int J Nanomedicine. 2017 Mar 16;12:2081-2108. [Content Brief]

Vincristine sulfate 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	1.0834 mL	5.4169 mL	10.8338 mL	27.0844 mL
	5 mM	0.2167 mL	1.0834 mL	2.1668 mL	5.4169 mL
	10 mM	0.1083 mL	0.5417 mL	1.0834 mL	2.7084 mL
	15 mM	0.0722 mL	0.3611 mL	0.7223 mL	1.8056 mL
	20 mM	0.0542 mL	0.2708 mL	0.5417 mL	1.3542 mL
	25 mM	0.0433 mL	0.2167 mL	0.4334 mL	1.0834 mL
	30 mM	0.0361 mL	0.1806 mL	0.3611 mL	0.9028 mL
	40 mM	0.0271 mL	0.1354 mL	0.2708 mL	0.6771 mL
	50 mM	0.0217 mL	0.1083 mL	0.2167 mL	0.5417 mL
DMSO	60 mM	0.0181 mL	0.0903 mL	0.1806 mL	0.4514 mL
DMSO	80 mM	0.0135 mL	0.0677 mL	0.1354 mL	0.3386 mL

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Vincristine2068-78-2LeurocristineNSC-6757422-Oxovincaleukoblastine硫酸长春新碱硫酸长春醛碱长春新碱硫化物长春新碱硫酸盐NSC67574NSC 67574Microtubule/TubulinApoptosisInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Vincristine sulfate (Synonyms: 硫酸长春新碱; Leurocristine sulfate; NSC-67574 sulfate; 22-Oxovincaleukoblastine sulfate)

Customer Review

Other Forms of Vincristine sulfate:

MCE 顾客使用本产品发表的 51 篇科研文献

Vincristine sulfate 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Vincristine sulfate 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Vincristine sulfate (Synonyms: 硫酸长春新碱; Leurocristine sulfate; NSC-67574 sulfate; 22-Oxovincaleukoblastine sulfate)

Customer Review

Other Forms of Vincristine sulfate:

Vincristine sulfate 相关抗体

MCE 顾客使用本产品发表的 51 篇科研文献

Vincristine sulfate 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Vincristine sulfate 相关抗体:

摩尔计算器

稀释计算器

Vincristine sulfate 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z